Lexology January 23, 2023
In Short
The Situation: With the calendar officially turned to a new year several significant changes and regulatory initiatives are on the horizon at the Food and Drug Administration (“FDA”).
The Result: From labeling guidance for alternative protein foods products, to implementation of cosmetic reform, to advancements in artificial intelligence, supply chain security, and digital health tools, 2023 is poised to be an active year at the FDA. Not to be outdone, the Federal Trade Commission (“FTC”) is primed to trigger largescale changes as it ushers in updates to several foundational documents governing its oversight of the advertising and marketing of FDA-regulated products.
Looking Ahead: As the year unfolds, industry participants should remain diligent of the evolving regulatory landscape and...
Today's Sponsors
Today's Sponsor